The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis
Authors:
- Weon-Kyoo YouWeon-Kyoo You
- Donald M. McDonaldDMDonald M. McDonald
Open Access
- 31 December 2008
- journal article
- review article
- Published by Korean Society for Biochemistry and Molecular Biology - BMB Reports in BMB Reports
- Vol. 41 (12) , 833-839
Abstract
The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis Angiogenesis inhibitors;Endothelial cells;HGFR;Receptor tyrosine kinases;Signal transduction;Tumors;VEGF;VEGFR; Angiogenesis in tumors is driven by multiple growth factors that activate receptor tyrosine kinases. An important driving force of angiogenesis in solid tumors is signaling through vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). Angiogenesis inhibitors that target this signaling pathway are now in widespread use for the treatment of cancer. However, when used alone, inhibitors of VEGF/VEGFR signaling do not destroy all blood vessels in tumors and do not slow the growth of most human cancers. VEGF/VEGFR signaling inhibitors are, therefore, used in combination with chemotherapeutic agents or radiation therapy. Additional targets for inhibiting angiogenesis would be useful for more efficacious treatment of cancer. One promising target is the signaling pathway of hepatocyte growth factor (HGF) and its receptor (HGFR, also known as c-Met), which plays important roles in angiogenesis and tumor growth. Inhibitors of this signaling pathway have been shown to inhibit angiogenesis in multiple in vitro and in vivo models. The HGF/c-Met signaling pathway is now recognized as a promising target in cancer by inhibiting angiogenesis, tumor growth, invasion, and metastasis.Keywords
This publication has 75 references indexed in Scilit:
- Biochemical Basis for the Functional Switch That Regulates Hepatocyte Growth Factor Receptor Tyrosine Kinase ActivationBiochemistry, 2008
- MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProceedings of the National Academy of Sciences, 2007
- Preclinical Efficacy of the c-Met Inhibitor CE-355621 in a U87 MG Mouse Xenograft Model Evaluated by18F-FDG Small-Animal PETJournal of Nuclear Medicine, 2007
- Food and Drug Administration Drug Approval Summary: Sunitinib Malate for the Treatment of Gastrointestinal Stromal Tumor and Advanced Renal Cell CarcinomaThe Oncologist, 2007
- A Novel One-Armed Anti-c-Met Antibody Inhibits Glioblastoma Growth In vivoClinical Cancer Research, 2006
- Discovery and development of sorafenib: a multikinase inhibitor for treating cancerNature Reviews Drug Discovery, 2006
- Mechanisms and significance of bifunctional NK4 in cancer treatmentBiochemical and Biophysical Research Communications, 2005
- Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic TherapyScience, 2005
- The Met kinase inhibitor SU11274 exhibits a selective inhibition pattern toward different receptor mutated variantsOncogene, 2004
- Using gene expression profiling to identify the molecular basis of the synergistic actions of hepatocyte growth factor and vascular endothelial growth factor in human endothelial cellsBritish Journal of Pharmacology, 2003